Stock TSHA TAYSHA GENE THERAPIES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Taysha Gene Therapies, Inc.

Equities

TSHA

US8776191061

Real-time Estimate Cboe BZX
Other stock markets
 10:43:20 2024-06-03 am EDT 		5-day change 1st Jan Change
3.905 USD +13.85% Intraday chart for Taysha Gene Therapies, Inc. +17.69% +116.10%
May. 14 Taysha Gene Therapies Q1 Net Loss Narrows, Revenue Declines -- Shares Down After Hours MT
May. 14 Transcript : Taysha Gene Therapies, Inc., Q1 2024 Earnings Call, May 14, 2024

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Taysha Gene Therapies Q1 Net Loss Narrows, Revenue Declines -- Shares Down After Hours
MT
Transcript : Taysha Gene Therapies, Inc., Q1 2024 Earnings Call, May 14, 2024
Taysha Gene Therapies, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Earnings Flash (TSHA) TAYSHA GENE THERAPIES Reports Q1 Revenue $3.4M, vs. Street Est of $2.6M
MT
Taysha Gene Therapies Reports First Quarter 2024 Financial Results and Provides Corporate Update
AQ
Taysha Gene Therapies to Release First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 14
AQ
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
AQ
Taysha Gene Therapies Announces Regenerative Medicine Advanced Therapy (RMAT) Designation Granted by U.S. FDA for TSHA-102 in Rett Syndrome
AQ
Taysha Gene Therapies Announces Regenerative Medicine Advanced Therapy Designation Granted by U.S. FDA for TSHA-102 in Rett Syndrome
CI
Piper Sandler Initiates Taysha Gene Therapies at Overweight Rating With $9 Price Target
MT
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
AQ
Chardan Adjusts PT on Taysha Gene Therapies to $7 From $5 as Gene Therapy for Rett Syndrome Shows 'Sustained Benefit', Keeps Buy Rating
MT
Wall Street Set to Open Flat as Investors Look Toward Fed Decision; Oil Prices Drop Sharply
MT
US Futures Flat in Wednesday's Premarket as Investors Await Fed's Interest Rate Decision
MT
Top Premarket Gainers
MT
Needham Adjusts Taysha Gene Therapies Price Target to $7 From $5, Maintains Buy Rating
MT
Taysha Gene Therapies Surges 26% Premarket After Full-Year 2023 Results Show Narrowing Net Loss, Surging Revenue
MT
North American Morning Briefing : Markets on Hold as Fed Decision Nears
DJ
Transcript : Taysha Gene Therapies, Inc., 2023 Earnings Call, Mar 19, 2024
Taysha Gene Therapies, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. TSHA Stock
  4. News Taysha Gene Therapies, Inc.